Related Experiment Video
Updated: Jan 26, 2026
In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
Published on: August 17, 2010
HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model
John S Schardt1,2, Madeleine Noonan-Shueh1, Jinan M Oubaid1
1Fischell Department of Bioengineering, University of Maryland, 3116 A. James Clark Hall, College Park, Maryland, 20742, USA.
Abstract:
Expression of the receptor tyrosine kinase HER3 is negatively correlated with survival in ovarian cancer, and HER3 overexpression is associated with cancer progression and therapeutic resistance. Thus, improvements in HER3-targeted therapy could lead to significant clinical impact for ovarian cancer patients. Previous work from our group established multivalency as a potential strategy to improve the therapeutic efficacy of HER3-targeted ligands, including affibodies. Others have established HER3 affibodies as viable and potentially superior alternatives to monoclonal antibodies for cancer therapy. Here, bivalent HER3 affibodies were engineered for optimized production, specificity, and function as evaluated in an ovarian cancer xenograft model. Enhanced inhibition of HER3-mediated signaling and increased HER3 downregulation associated with multivalency could be achieved with a simplified construct, potentially increasing translational potential. Additionally, functional effects of affibodies due to multivalency were found to be specific to HER3 targeting, suggesting a unique molecular mechanism. Further, HER3 affibodies demonstrated efficacy in ovarian cancer xenograft mouse models, both as single agents and in combination with carboplatin. Overall, these results reinforce the potential of HER3-targeted affibodies for cancer therapy and establish treatment of ovarian cancer as an application where multivalent HER3 ligands may be useful. Further, this work introduces the potential of HER3 affibodies to be utilized as part of clinically relevant combination therapies (e.g., with carboplatin).
Insights
Engineered multivalent HER3 affibodies show promise for ovarian cancer therapy, enhancing HER3 inhibition and demonstrating efficacy in xenograft models, alone and with carboplatin.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- HER3 (human epidermal growth factor receptor 3) overexpression correlates with poor survival and therapeutic resistance in ovarian cancer.
- Targeting HER3 presents a significant clinical opportunity for improving ovarian cancer treatment outcomes.
- Affibodies are emerging as potent alternatives to monoclonal antibodies for cancer therapy.
Purpose of the Study:
- To engineer and evaluate bivalent HER3 affibodies for optimized production, specificity, and therapeutic function in ovarian cancer.
- To investigate the impact of multivalency on HER3-targeted affibody efficacy and signaling inhibition.
- To assess the potential of HER3 affibodies as single agents and in combination therapies for ovarian cancer.
Main Methods:
- Engineering of bivalent HER3 affibody constructs.
- In vitro assessment of HER3 signaling inhibition and HER3 downregulation.
- In vivo evaluation in ovarian cancer xenograft mouse models.
- Combination therapy studies with carboplatin.
Main Results:
- Engineered bivalent HER3 affibodies demonstrated enhanced inhibition of HER3-mediated signaling and increased HER3 downregulation.
- Multivalency conferred specific functional effects on HER3 targeting, suggesting a unique mechanism.
- HER3 affibodies showed significant efficacy in ovarian cancer xenograft models as single agents.
- Combination therapy with carboplatin further enhanced the therapeutic effect.
Conclusions:
- Multivalent HER3 affibodies represent a promising strategy for ovarian cancer therapy.
- Simplified constructs may increase the translational potential of HER3-targeted affibody therapies.
- HER3 affibodies show potential for use in clinically relevant combination therapies, such as with carboplatin.
More Related Videos
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
12:42Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:27Ovarian Cycle